ApconiX are experts in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.
ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company founded on the skills and experience of a growing team with a wide range of expertise in nonclinical drug safety.
The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners. There are many more SMEs and academic groups who also need access to specialised services.
ApconiX addresses all needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way. In this way, companies work with people they trust, to make better decisions on drug safety.
Collaborating across the globe
The market need has been demonstrated by the remarkable growth of ApconiX. The current client list is spread across the globe.
ApconiX has embarked on several strategic international alliances. In collaborating with the French company PhysioStim, ApconiX has become part of a European centre of excellence for preclinical cardiovascular safety evaluation. The recent alliance with Sygnature Discovery ensures the Nottingham based CRO can provide its customers with a broader range of drug discovery services.
ApconiX is continually forming collaborative relationships, helping customers large and small. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate the difficult pathway towards safe, effective and profitable drugs.